Recent Advances in Extracorporeal Cardiac Shock Wave Therapy for Ischemic Heart Disease

Q: What is the clinical evidence from this study?

Study design: Review. Population: Ischemic heart disease (including refractory angina and ischemic heart failure). Intervention: Extracorporeal cardiac shock wave therapy (CSWT) vs. Placebo, sham procedure, standard medical therapy, or enhanced external counterpulsation (EECP).

Q: What does this research mean for the field?

Extracorporeal cardiac shock wave therapy at standard energy densities (0.024-0.090 mJ/mm²) safely improves angina symptoms, myocardial perfusion, left ventricular systolic function, and short-term readmission rates in stable ischemic heart disease. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Jiuqi Liu

doi:10.12677/acm.2026.16103467

January 1, 2026Advances in Clinical MedicineOpen Access

Recent Advances in Extracorporeal Cardiac Shock Wave Therapy for Ischemic Heart Disease

View Full Paper

Ask AI

Bookmark

Share

Key result

Cardiac shock wave therapy safely improves symptoms, perfusion, and systolic function in stable IHD.

Why the study?

Ischemic heart disease is a major global public health problem and the leading cause of cardiovascular death in China, while clinical intervention strategies for patients with advanced severe disease still have significant limitations.

Key Points

To review the clinical evidence and underlying biological mechanisms of extracorporeal cardiac shock wave therapy as a non-invasive rehabilitation approach for ischemic heart disease.
Narrative review synthesizing clinical trials and preclinical mechanistic studies evaluating extracorporeal cardiac shock wave therapy in patients with ischemic heart disease and refractory angina.
Summarized evidence on standard therapeutic regimens, typically using energy densities between 0.024 and 0.090 mJ/mm² across 9 sessions targeting 9 to 16 myocardial zones.
Clinical studies demonstrate that cardiac shock wave therapy improves Canadian Cardiovascular Society angina scores, New York Heart Association functional class, 6-minute walk distance, and left ventricular ejection fraction.
Therapy improves regional myocardial perfusion, reduces short-term cardiovascular readmissions (e.g., 14% vs. 45.5%), and enhances quality of life without increasing ischemic events or malignant arrhythmias.
Mechanistic evidence shows shock waves stimulate coronary angiogenesis via VEGF and nitric oxide signaling, inhibit cardiomyocyte apoptosis, reduce inflammation and oxidative stress, and attenuate myocardial fibrosis.

PICO

P

Population

Stable patients with ischemic heart disease, such as refractory angina (CCS class II or higher) or ischemic heart failure (NYHA class I-III), with reversible myocardial ischemia who are unsuitable for or refuse PCI/CABG.

I

Intervention / Comparator

Extracorporeal cardiac shock wave therapy (CSWT) vs Placebo, sham procedure, standard medical therapy, or enhanced external counterpulsation (EECP) (0.024-0.090 mJ/mm2, 9 sessions per course, 9-16 target spots per session)

Limitations

Existing clinical studies have small sample sizes, high heterogeneity, lack sham control groups in some trials, and lack large-scale randomized controlled trials
Lack of long-term follow-up data limits evaluation of long-term efficacy, safety, and scope of application
Outcome assessment tools in some studies are relatively outdated, requiring more sensitive imaging modalities like stress echocardiography or D-SPECT
Very few studies directly evaluate the impact of CSWT on cardiac diastolic function
Mechanistic studies are mainly limited to improving myocardial ischemia, and whether CSWT directly regulates inflammatory pathways remains to be elucidated

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Shows that extracorporeal cardiac shock wave therapy improves myocardial perfusion and systolic function in ischemic heart disease, indicating its potential as a non-invasive rehabilitation therapy.

Abstract

Ischemic heart disease remains a major global public health problem and is also the leading cause

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jiuqi Liu (2026) conducted a review in Ischemic heart disease (including refractory angina and ischemic heart failure). Extracorporeal cardiac shock wave therapy (CSWT) vs. Placebo, sham procedure, standard medical therapy, or enhanced external counterpulsation (EECP) was evaluated. Extracorporeal cardiac shock wave therapy safely improves angina symptoms, myocardial perfusion, left ventricular systolic function, and short-term readmission in stable IHD.

synapsesocial.com/papers/6af0cd87afd0f3f56e51a214 https://doi.org/10.12677/acm.2026.16103467

View Full Paper

Ask AI

Bookmark

Share

Recent Advances in Extracorporeal Cardiac Shock Wave Therapy for Ischemic Heart Disease

Key Points

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Recent Advances in Extracorporeal Cardiac Shock Wave Therapy for Ischemic Heart Disease

Key Points

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading